Trastuzumab Deruxtecan Treatment for Metastatic HER2+ Breast Cancer with Brain Metastases

Video

Experts have a conversation of the use of trastuzumab deruxtecan therapy for patients with progressive brain metastases while weighing common toxicities and clinical trial data.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Early Efficacy Seen With Gedatolisib-Based Therapies Prostate/Breast Cancers

Tim Cortese
June 30th 2025
Article

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article